Page 148 - Assessing right ventricular function and the pulmonary circulation in pulmonary hypertension Onno Anthonius Spruijt

8
[24] Frings V YM, Hoyng LL, Golla SS, Windhorst AD, Schuit RC, Lammertsma AA, Hoekstra OS, Smit EF, Boellaard R; for QuIC‐ConCePT Consortium. Assessment of simplified methods to measure 18F‐FLT uptake changes in EGFR‐mutated non‐small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment. J Nucl Med. 2014; 55:1417‐1423.
[25] van de Veerdonk MC KT, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, Vonk‐Noordegraaf A. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011; 58:2511‐2519.
[26] Frings V dLA, Yaqub M, Schuit RC, van der Veldt AA, Hoekstra OS, Smit EF, Boellaard R. Methodological Considerations in Quantification of 3'‐Deoxy‐3'‐[18F]Fluorothymidine Uptake Measured with Positron Emission Tomography in Patients with Non‐Small Cell Lung Cancer. Mol Imaging Biol. 2014; 16:136‐145.
[27] Hoekstra CJ HO, Lammertsma AA. On the use of the injection catheter for venous blood sampling in quantitative FDG PET studies. Eur J Nucl Med. 2000; 27:1579.
[28] Akaike H. A new look at the statistical model identification. IEEE Transactions on automatic control. 1974; 19:716‐ 723.
[29] Muzi MM, DA.; Grierson, JR.; Wells, JM.; Vesselle, H.; Krohn, KA. Kinetic modeling of 3'‐deoxy‐3'‐fluorothymidine in somatic tumors: mathematical studies. J Nucl Med. 2005; 46:371‐380.
[30] Ghigna MR, Guignabert C, Montani D, Girerd B, Jais X, Savale L, Herve P, Thomas de Montpreville V, Mercier O, Sitbon O, Soubrier F, Fadel E, Simonneau G, Humbert M and Dorfmuller P. BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. Eur Respir J. 2016.
[31] Munk OL. Model‐independent plot of dynamic PET data facilitates data interpretation and model selection. J Theor Biol. 2012; 295:1‐8.
[32] Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN and Hetzel M. Imaging proliferation in lung tumors with PET: 18F‐FLT versus 18F‐FDG. J Nucl Med. 2003; 44:1426‐31.
[33] van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, de Vries EF, Jager PL, Hoekstra HJ and Elsinga PH. Selectivity of 18F‐FLT and 18F‐FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004; 45:695‐700. [34] Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, Kanaji N, Haba R, Kushida Y and Ohkawa M. Correlation of 18F‐FLT and 18F‐FDG uptake on PET with Ki‐67 immunohistochemistry in non‐small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007; 34:1610‐6.
[35] Yamamoto Y, Nishiyama Y, Kimura N, Ishikawa S, Okuda M, Bandoh S, Kanaji N, Asakura M and Ohkawa M. Comparison of (18)F‐FLT PET and (18)F‐FDG PET for preoperative staging in non‐small cell lung cancer. Eur J Nucl Med Mol Imaging. 2008; 35:236‐45.
[36] Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME and Weber WA. Evaluation of thoracic tumors with 18F‐fluorothymidine and 18F‐fluorodeoxyglucose‐positron emission tomography. Chest. 2006; 129:393‐401.
[37] Tehrani OS and Shields AF. PET imaging of proliferation with pyrimidines. J Nucl Med. 2013; 54:903‐12.